Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Volker Mobus"'
Autor:
Mattea Reinisch, Michael Untch, Rolf Mahlberg, Toralf Reimer, Thomas Hitschold, Frederik Marmé, Mustafa Aydogdu, Sabine Schmatloch, Hans-Joachim Lück, Marcus Schmidt, Ekkehart Ladda, Bruno Valentin Sinn, Peter Klare, Wolfgang Janni, Christian Jackisch, Carsten Denkert, Sabine Seiler, Thomas Göhler, Laura Michel, Nicole Burchardi, Elmar Stickeler, Julia Rey, Nicole Klutinus, Volker Möbus, Sibylle Loibl
Publikováno v:
Breast, Vol 66, Iss , Pp 110-117 (2022)
Background: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into th
Externí odkaz:
https://doaj.org/article/916f38f5626a45b9afb718606995934e
Autor:
Christine Stürken, Volker Möbus, Karin Milde-Langosch, Sabine Schmatloch, Peter A. Fasching, Josef Rüschoff, Elmar Stickeler, Rolf-Peter Henke, Carsten Denkert, Lars Hanker, Christian Schem, Valentina Vladimirova, Thomas Karn, Valentina Nekljudova, Claus-Henning Köhne, Frederik Marmé, Udo Schumacher, Sibylle Loibl, Volkmar Müller
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Breast cancer (BC) is the most frequent female cancer and preferentially metastasizes to bone. The transcription factor TGFB-induced factor homeobox 1 (TGIF) is involved in bone metabolism. However, it is not yet known whether TGI
Externí odkaz:
https://doaj.org/article/c69ff00bda2f4529a85614e57c4f1988
Autor:
Christine Stürken, Volker Möbus, Karin Milde-Langosch, Sabine Schmatloch, Peter A. Fasching, Josef Rüschoff, Elmar Stickeler, Rolf-Peter Henke, Carsten Denkert, Lars Hanker, Christian Schem, Valentina Vladimirova, Thomas Karn, Valentina Nekljudova, Claus-Henning Köhne, Frederik Marmé, Udo Schumacher, Sibylle Loibl, Volkmar Müller
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/c9d26cf8ebe64f5d8bb80d323fe092e0
Autor:
Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, Peter Klare, Knut Engels, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marmé, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Sabine Seiler, Christine Solbach, Sabine Schmatloch, Julia Rey, Sibylle Loibl
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n = 2887) were rando
Externí odkaz:
https://doaj.org/article/b93eb5cc3e364be681372848cc75b63c
Autor:
Martine Piccart, Volker Mobus, Investigators, Jennifer Eng-Wong, José Baselga, Thomas Suter, Giuseppe Viale, Amal Arahmani, José Bines, Emma Clark, Richard D. Gelber, Marion Procter, Eleonora Restuccia, Veerle Van Dooren, Evandro de Azambuja, Dimitrios Zardavas
Publikováno v:
Clinical Breast Cancer. 20:174-181.e3
Background The APHINITY (BIG 4-11) study showed that pertuzumab significantly improved the rates of invasive disease-free survival among patients with human epidermal growth factor receptor 2 (HER2)-positive, operable breast cancer when added to adju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79100653a898a64f280b597ef369216b
https://doi.org/10.1016/j.clbc.2019.06.016
https://doi.org/10.1016/j.clbc.2019.06.016
Autor:
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cynthia Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset Halim, Christopher D. Turner, Denise A. Yardley
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. Th
Externí odkaz:
https://doaj.org/article/17180d15d53a444b97cb83ce78fb7480
Autor:
Elena Laakmann, Isabell Witzel, Verena Scriba, Ulrich Grzyska, Christine zu Eulenburg, Nicole Burchardi, Tobias Hesse, Florian Würschmidt, Tanja Fehm, Volker Möbus, Gunter von Minckwitz, Sibylle Loibl, Tjoung-Won Park-Simon, Volkmar Mueller
Publikováno v:
International Journal of Molecular Sciences, Vol 17, Iss 10, p 1615 (2016)
Evidence about distribution patterns of brain metastases with regard to breast cancer subtypes and its influence on the prognosis of patients is insufficient. Clinical data, cranial computed tomography (CT) and magnetic resonance imaging (MRI) scans
Externí odkaz:
https://doaj.org/article/1fe775039bd6438387845e76ae17c487